FORESIGHT is transforming drug development by using advanced molecular imaging to track medicines in the body and identify the best treatment for each patient. This innovative approach makes drug development faster, more effective, and more personalized, helping to bring better treatments to those who need them most.
Chronic and severe diseases pose an increasing burden on society. The number of patients is expected to rise sharply, overwhelming healthcare systems and driving costs to unsustainable levels. Despite the urgent need for new treatments, drug development remains highly inefficient-taking an average of 10 years and costing at least €1 billion per drug, with a high failure rate. Even among approved medicines, 90% do not work for all patients. Additionally, diagnostic imaging-which could help predict drug efficacy and personalize treatments-is rarely used in development or clinical practice.
FORESIGHT addresses these challenges by applying molecular nuclear and optical imaging to develop imaging biomarkers-providing tools for cell-level tissue mapping till real-time drug tracking in the body.
This is achieved by identifying the right patients for specific treatments and increasing drug effectiveness, optimizing clinical trial design, making development faster and more cost-effective. By integrating these technologies, FORESIGHT enhances precision medicine, ensuring patients receive the most effective treatments.
UMCG, AUMC, NKI/AVL and TU/e have combined their high-quality expertise and infrastructure in the FORESIGHT Service and Innovation Center. This R&D Center collaborates with (inter)national companies and agencies. Multidisciplinary teams with unique knowledge of tracer development, bioengineering, imaging and data analysis/AI support the teams performing (pre)clinical molecular imaging studies. The FORESIGHT-PPP program can demonstrate the impact of imaging with compelling public-private innovative development projects, thereby accelerating sustainable growth of the Center.
By combining strengths in tracer development, bioengineering, imaging, and AI-driven data analysis, FORESIGHT aims to transform drug development and precision medicine.
The FORESIGHT PPP program is made possible via the Public-Private Partnership (PPP) subsidy scheme introduced by the Top Consortium for Knowledge and Innovation - Life Sciences & Health (TKI-LSH aka Health~Holland). Through the program, parties have the opportunity to apply for PPP projects with the PPP subsidy from Health~Holland.
An amount of 9 Million Euros PPP subsidy was awarded to the Program to distribute among and support collaborative projects by issuing yearly Calls for projects to run between 2025 and 2032.
Below you find additional information about the consortium and the funding scheme. For questions, please reach out to [email protected]
The FORESIGHT Program is part of the Health Holland PPP subsidy scheme which aims to develop partnerships with industry, by issuing yearly calls for projects, allocate resources, and oversee their implementation.
The FORESIGHT-PPP projects accelerate innovations through applied research focused on the optimal use of molecular imaging within drug development projects, enabling translation to clinical phase 1-2 studies and personalized drug treatment. The core modules are:
(Pre)clinical development projects are conducted in the following disease areas:
Through the FORESIGHT program, parties have the opportunity to jointly apply for PPP projects with a request for PPP subsidy from Health~Holland.
The PPP subsidy available is 9 M EUR, divided into three program periods between 1 January 2025 and 31 December 2032. The expectation is to realize about 20 innovative projects evenly distributed across the four FORESIGHT disease areas. Through these innovations, the program will demonstrate the power of molecular imaging, in drug development or choice, driving long-term growth in precision medicine.
For information on requirements, timelines and eligibility criteria, please consult the call description and the slide deck provided below. For questions, please reach out at [email protected]
Proposals are assessed in two stages. Pre-applications can be submitted at anytime during the indicated submission periods. The application templates below are mandatory to use. If selected for the full application phase, the applicant will receive further instructions regarding the documents for the next phase.
After evaluation, the assessment committee strives to communicate about the selected pre-proposals by 1 July 2025 and about the awarded full proposals by 1 November 2025.
After evaluation, the assessment committee strives to communicate about the selected pre-proposals by 20 December 2025 and about the awarded full proposals by 1 April 2026.
Upcoming online information sessions:
To register, please reach out at [email protected]
For the pre-application phase, it is required to submit:
For the full application phase, it is required to submit:
Documents and templates for consultation and for full submission phase:
For submitting the application and more information on the procedures and requirements, please contact [email protected]
